Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses

NCT00707473 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00707473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00707473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
June 16, 2008
Completion date
June 1, 2026
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced nasal cavity and paranasal sinus squamous cell carcinoma, nasal cavity and paranasal sinus poorly differentiated carcinoma, sinonasal undifferentiated carcinoma, stage ii nasal cavity and paranasal sinus cancer ajcc v8, stage iii nasal cavity and paranasal sinus cancer ajcc v8, stage iva nasal cavity and paranasal sinus cancer ajcc v8, stage ivb nasal cavity and paranasal sinus cancer ajcc v8